



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/808,832	03/15/2001	Robert A. Copeland	PH-7134

CONFIRMATION NO. 5618

## FORMALITIES LETTER



\*OC00000006056391\*

24348  
Dupont Pharmaceuticals Company  
Legal Department - Patents  
1007 Market Street  
Wilmington, DE 19898

Date Mailed: 05/09/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

07/03/2001 NYUSUF1 00000001 041920 09000032

01 FC:105 130.00 CH

*A copy of this notice MUST be returned with the reply.*

A handwritten signature in black ink, appearing to be "T. Hall", written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Attorney Dkt. No. PH-7134

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Copeland	)	
U.S. Serial No.:	09/808,832	)	Examiner: Not Yet Assigned
Filed:	03/15/01	)	Art Unit: Not Yet Assigned
For:	Peptidase-Cleavable, Targeted Antineoplastic Drugs And Their Therapeutic Use	)	

Hon. Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO FILE MISSING PARTS**

This communication is in response to the Notice to File Missing Parts mailed May 9, 2001. Applicants respectfully request reconsideration in view of the following remarks.

**REMARKS**

In response to the Notice to File Missing Parts the Applicants are submitting herewith a signed Declaration. Authorization is also given to charge a surcharge in the amount of \$130.00 for the late filing of the signed Declaration to Deposit Account 04-1928 (E.I. du Pont de Nemours and Company).

In addition, Applicants have been informed that while a copy of the Sequence Listing in computer readable form has been submitted, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823 as indicated on the marked-up "Raw Sequence Listing."

A copy of a marked-up "Raw Sequence Listing" is enclosed here along with this response as required by the Notice to File Missing Parts. Also, Applicants are providing the U.S. Patent Office the following:


- (1) An substitute computer readable form (CRF) copy of the "Sequence Listing";
- (2) An substitute paper copy of the "Sequence Listing", as well as this amendment directing its entry into the specification (stated above); and
- (3) A statement that the content of the paper and computer readable copies are the same and includes no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) (following below).

The Applicants direct the entry of the substitute CRF copy of the "Sequence Listing" along with a substitute paper copy of same into the specification. Applicants further state that the contents of the paper and CRF copies of the "Sequence Listing" are the same and include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Applicants maintain that the application is now in condition for substantive examination, and early notice to that effect is respectfully requested. No fee is deemed necessary in connection with this response's filing other than the \$130.00 surcharge required in connection with the late filing of the signed Declaration. However, if any other fee is deemed necessary, authorization is hereby given to charge the amount of such a fee to Deposit Account No. 04-1928.

6-26-01  
(Date)

Respectfully submitted,

  
Kalim S. Fuzail  
Attorney for Applicant  
Registration No. 45,805  
Telephone: 302-992-3215

**PH-7134 Response (June 2001).doc**



## Certificate of Mailing under 37 CFR 1.8

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In the Application of:**

**Robert A. Copeland et al**

**CASE NO.: PH-7134**

**APPLICATION NO.: 09/808,832**

**GROUP ART UNIT: 1614**

**FILED: MARCH 15, 2001**

**EXAMINER: UNKNOWN**

**FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE**

I hereby certify that this correspondence, a **Notice to File Missing Parts, Fee Transmittal Sheet, Declaration (3 pages), Power of Attorney (10 pages), Marked-Up Copy of Sequence List, Disc, PTO Copy of Notice to File Missing Parts, and Sequence Listing**, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

*June 26, 2001*  
Date

*Diana C. Pickering*  
Signature

*Diana C. Pickering*  
Type or printed name of person signing Certificate

**Note:** Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FREE TRANSMITTAL**  
**for FY 2001**

Patent fees are subject to annual revision.

**TOTAL AMOUNT OF PAYMENT** (\$ ) 130.00

**Complete if Known**

Application Number	09/808,832
Filing Date	March 15, 2001
First Named Inventor	Copeland et al
Examiner Name	Unknown
Group / Art Unit	1614
Attorney Docket No.	PH-7134

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)																																																																																																																																																																															
<p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:</p> <p>Deposit Account Number: <b>04-1928</b></p> <p>Deposit Account Name: <b>DuPont Pharmaceuticals Company</b></p> <p><input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17</p> <p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27</p> <p>2. <input type="checkbox"/> Payment Enclosed:</p> <p><input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other</p>		<p><b>3. ADDITIONAL FEES</b></p> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>105</td> <td>130</td> <td>205</td> <td>65</td> <td>Surcharge - late filing fee or oath</td> <td>130</td> </tr> <tr> <td>127</td> <td>50</td> <td>227</td> <td>25</td> <td>Surcharge - late provisional filing fee or cover sheet.</td> <td></td> </tr> <tr> <td>139</td> <td>130</td> <td>139</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>147</td> <td>2,520</td> <td>147</td> <td>2,520</td> <td>For filing a request for ex parte reexamination</td> <td></td> </tr> <tr> <td>112</td> <td>920*</td> <td>112</td> <td>920*</td> <td>Requesting publication of SIR prior to Examiner action</td> <td></td> </tr> <tr> <td>113</td> <td>1,840*</td> <td>113</td> <td>1,840*</td> <td>Requesting publication of SIR after Examiner action</td> <td></td> </tr> <tr> <td>115</td> <td>110</td> <td>215</td> <td>55</td> <td>Extension for reply within first month</td> <td></td> </tr> <tr> <td>116</td> <td>390</td> <td>216</td> <td>195</td> <td>Extension for reply within second month</td> <td></td> </tr> <tr> <td>117</td> <td>890</td> <td>217</td> <td>445</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>118</td> <td>1,390</td> <td>218</td> <td>695</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>128</td> <td>1,890</td> <td>228</td> <td>945</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>119</td> <td>310</td> <td>219</td> <td>155</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>120</td> <td>310</td> <td>220</td> <td>155</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>121</td> <td>270</td> <td>221</td> <td>135</td> <td>Request for oral hearing</td> <td></td> </tr> <tr> <td>138</td> <td>1,510</td> <td>138</td> <td>1,510</td> <td>Petition to institute a public use proceeding</td> <td></td> </tr> <tr> <td>140</td> <td>110</td> <td>240</td> <td>55</td> <td>Petition to revive - unavoidable</td> <td></td> </tr> <tr> <td>141</td> <td>1,240</td> <td>241</td> <td>620</td> <td>Petition to revive - unintentional</td> <td></td> </tr> <tr> <td>142</td> <td>1,240</td> <td>242</td> <td>620</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>143</td> <td>440</td> <td>243</td> <td>220</td> <td>Design issue fee</td> <td></td> </tr> <tr> <td>144</td> <td>600</td> <td>244</td> <td>300</td> <td>Plant issue fee</td> <td></td> </tr> <tr> <td>122</td> <td>130</td> <td>122</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>123</td> <td>130</td> <td>123</td> <td>50</td> <td>Petitions related to provisional applications</td> <td></td> </tr> <tr> <td>126</td> <td>240</td> <td>126</td> <td>240</td> <td>Submission of Information Disclosure Stmt</td> <td></td> </tr> <tr> <td>581</td> <td>40</td> <td>581</td> <td>40</td> <td>Recording each patent assignment per property (times number of properties)</td> <td></td> </tr> <tr> <td>146</td> <td>710</td> <td>246</td> <td>355</td> <td>Filing a submission after final rejection (37 CFR § 1.129(a))</td> <td></td> </tr> <tr> <td>149</td> <td>710</td> <td>249</td> <td>355</td> <td>For each additional invention to be examined (37 CFR § 1.129(b))</td> <td></td> </tr> <tr> <td>179 (RCE)</td> <td>710</td> <td>279</td> <td>355</td> <td>Request for Continued Examination</td> <td></td> </tr> <tr> <td>169</td> <td>900</td> <td>169</td> <td>900</td> <td>Request for expedited examination of a design application</td> <td></td> </tr> </tbody> </table> <p>Other fee (specify)</p> <p>*Reduced by Basic Filing Fee Paid</p> <p><b>SUBTOTAL (3)</b> (\$ ) 130.00</p>		Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	105	130	205	65	Surcharge - late filing fee or oath	130	127	50	227	25	Surcharge - late provisional filing fee or cover sheet.		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for ex parte reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month		116	390	216	195	Extension for reply within second month		117	890	217	445	Extension for reply within third month		118	1,390	218	695	Extension for reply within fourth month		128	1,890	228	945	Extension for reply within fifth month		119	310	219	155	Notice of Appeal		120	310	220	155	Filing a brief in support of an appeal		121	270	221	135	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,240	241	620	Petition to revive - unintentional		142	1,240	242	620	Utility issue fee (or reissue)		143	440	243	220	Design issue fee		144	600	244	300	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	130	123	50	Petitions related to provisional applications		126	240	126	240	Submission of Information Disclosure Stmt		581	40	581	40	Recording each patent assignment per property (times number of properties)		146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))		149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))		179 (RCE)	710	279	355	Request for Continued Examination		169	900	169	900	Request for expedited examination of a design application	
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
105	130	205	65	Surcharge - late filing fee or oath	130																																																																																																																																																																												
127	50	227	25	Surcharge - late provisional filing fee or cover sheet.																																																																																																																																																																													
139	130	139	130	Non-English specification																																																																																																																																																																													
147	2,520	147	2,520	For filing a request for ex parte reexamination																																																																																																																																																																													
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																													
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																													
115	110	215	55	Extension for reply within first month																																																																																																																																																																													
116	390	216	195	Extension for reply within second month																																																																																																																																																																													
117	890	217	445	Extension for reply within third month																																																																																																																																																																													
118	1,390	218	695	Extension for reply within fourth month																																																																																																																																																																													
128	1,890	228	945	Extension for reply within fifth month																																																																																																																																																																													
119	310	219	155	Notice of Appeal																																																																																																																																																																													
120	310	220	155	Filing a brief in support of an appeal																																																																																																																																																																													
121	270	221	135	Request for oral hearing																																																																																																																																																																													
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																													
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																													
141	1,240	241	620	Petition to revive - unintentional																																																																																																																																																																													
142	1,240	242	620	Utility issue fee (or reissue)																																																																																																																																																																													
143	440	243	220	Design issue fee																																																																																																																																																																													
144	600	244	300	Plant issue fee																																																																																																																																																																													
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																													
123	130	123	50	Petitions related to provisional applications																																																																																																																																																																													
126	240	126	240	Submission of Information Disclosure Stmt																																																																																																																																																																													
581	40	581	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																													
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))																																																																																																																																																																													
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))																																																																																																																																																																													
179 (RCE)	710	279	355	Request for Continued Examination																																																																																																																																																																													
169	900	169	900	Request for expedited examination of a design application																																																																																																																																																																													
<p><b>FEE CALCULATION</b></p> <p>1. <b>BASIC FILING FEE</b></p> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>101</td> <td>710</td> <td>201</td> <td>355</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>106</td> <td>320</td> <td>206</td> <td>160</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>107</td> <td>490</td> <td>207</td> <td>245</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>108</td> <td>710</td> <td>208</td> <td>355</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>114</td> <td>150</td> <td>214</td> <td>75</td> <td>Provisional filing fee</td> <td></td> </tr> </tbody> </table> <p><b>SUBTOTAL (1)</b> (\$ )</p> <p>2. <b>EXTRA CLAIM FEES</b></p> <table border="1"> <thead> <tr> <th>Total Claims</th> <th>Extra Claims</th> <th>Fee from below</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Independent Claims</td> <td>-20** = 0</td> <td>X</td> <td>= 0</td> </tr> <tr> <td>Multiple Dependent</td> <td>-3** = 0</td> <td>X</td> <td>= 0</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Large Fee Code</th> <th>Entity Fee (\$)</th> <th>Small Fee Code</th> <th>Entity Fee (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>103</td> <td>18</td> <td>203</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>102</td> <td>80</td> <td>202</td> <td>40</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>104</td> <td>270</td> <td>204</td> <td>135</td> <td>Multiple dependent claim, if not paid</td> <td></td> </tr> <tr> <td>109</td> <td>80</td> <td>209</td> <td>40</td> <td>** Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>110</td> <td>18</td> <td>210</td> <td>9</td> <td>** Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> </tbody> </table> <p><b>SUBTOTAL (2)</b> (\$ )</p>		Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	101	710	201	355	Utility filing fee		106	320	206	160	Design filing fee		107	490	207	245	Plant filing fee		108	710	208	355	Reissue filing fee		114	150	214	75	Provisional filing fee		Total Claims	Extra Claims	Fee from below	Fee Paid	Independent Claims	-20** = 0	X	= 0	Multiple Dependent	-3** = 0	X	= 0	Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid	103	18	203	9	Claims in excess of 20		102	80	202	40	Independent claims in excess of 3		104	270	204	135	Multiple dependent claim, if not paid		109	80	209	40	** Reissue independent claims over original patent		110	18	210	9	** Reissue claims in excess of 20 and over original patent		<p>**or number previously paid, if greater; For Reissues, see above</p>																																																																																											
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
101	710	201	355	Utility filing fee																																																																																																																																																																													
106	320	206	160	Design filing fee																																																																																																																																																																													
107	490	207	245	Plant filing fee																																																																																																																																																																													
108	710	208	355	Reissue filing fee																																																																																																																																																																													
114	150	214	75	Provisional filing fee																																																																																																																																																																													
Total Claims	Extra Claims	Fee from below	Fee Paid																																																																																																																																																																														
Independent Claims	-20** = 0	X	= 0																																																																																																																																																																														
Multiple Dependent	-3** = 0	X	= 0																																																																																																																																																																														
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid																																																																																																																																																																												
103	18	203	9	Claims in excess of 20																																																																																																																																																																													
102	80	202	40	Independent claims in excess of 3																																																																																																																																																																													
104	270	204	135	Multiple dependent claim, if not paid																																																																																																																																																																													
109	80	209	40	** Reissue independent claims over original patent																																																																																																																																																																													
110	18	210	9	** Reissue claims in excess of 20 and over original patent																																																																																																																																																																													


SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Kalim S. Fuzail	Registration No. Attorney/Agent	45,805	Telephone	302-992-3215
Signature		Date	6-26-01		

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



04/001  
06/15/2001



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

09/808,832

Source:

OIPE

Date Processed by STIC:

3/30/2001

**THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.**

**PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:**

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

**FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.**

**FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.**

**PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)**

**PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)**

**TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:**

### **Checker Version 3.0**

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST 25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

**Checker Version 3.0 can be downloaded from the USPTO website at the following address:**



## Raw Sequence Listing Error Summary

**ERROR DETECTED SUGGESTED CORRECTION**

SERIAL NUMBER: 09/808,832

**ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE**

- 1        Wrapped Nucleics      The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2        Wrapped Aminos      The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3        Incorrect Line Length      The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4        Misaligned Amino Acid      The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs  
Numbering      between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5        Non-ASCII      This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 5        Variable Length      Sequence(s)        contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and  
indicate in the (ix) feature section that some may be missing.
- 7        PatentIn ver. 2.0 "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid  
sequence(s)       . Normally, PatentIn would automatically generate this section from the  
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section  
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>  
sections for Artificial or Unknown sequences.
- 8        Skipped Sequences      Sequence(s)        missing. If intentional, please use the following format for each skipped sequence:  
(OLD RULES)      (2) INFORMATION FOR SEQ ID NO:X:  
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9        Skipped Sequences      Sequence(s)        missing. If intentional, please use the following format for each skipped sequence.  
(NEW RULES)      <210> sequence id number  
<400> sequence id number  
000
- 10        Use of n's or Xaa's      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
(NEW RULES)      Use of <220> to <223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11        Use of <213>Organism      Sequence(s)        are missing this mandatory field or its response.  
(NEW RULES)
- 12        Use of <220>Feature      Sequence(s)        are missing the <220>Feature and associated headings.  
(NEW RULES)      Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"  
Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13        PatentIn ver. 2.0 "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted  
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).  
Instead, please use "File Manager" or any other means to copy file to floppy disk.





OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:26

*pp 1-5*

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: DuPont Pharmaceuticals Company  
5 <120> TITLE OF INVENTION: Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic

6 use

8 <130> FILE REFERENCE: PH-7134

C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/808,832

C--> 10 <141> CURRENT FILING DATE: 2001-03-15

10 <150> PRIOR APPLICATION NUMBER: 60/189,387

11 <151> PRIOR FILING DATE: 2000-03-15

13 <160> NUMBER OF SEQ ID NOS: 210

15 <170> SOFTWARE: PatentIn version 3.0

17 <210> SEQ ID NO: 1

18 <211> LENGTH: 5

19 <212> TYPE: PRT

20 <213> ORGANISM: Artificial

22 <220> FEATURE:

23 <223> OTHER INFORMATION: no comment

25 <220> FEATURE:

26 <221> NAME/KEY: MOD\_RES

27 <222> LOCATION: (1)..(1)

28 <223> OTHER INFORMATION: 4-methoxy-benzenesulfonyl-beta-alanine

31 <220> FEATURE:

32 <221> NAME/KEY: MOD\_RES

33 <222> LOCATION: (3)..(3)

34 <223> OTHER INFORMATION: homophenylalanine

37 <400> SEQUENCE: 1

39 Xaa Gly Xaa Tyr Leu

40 1 5

42 <210> SEQ ID NO: 2

43 <211> LENGTH: 5

44 <212> TYPE: PRT

45 <213> ORGANISM: Artificial

47 <220> FEATURE:

48 <223> OTHER INFORMATION: no comment

50 <220> FEATURE:

51 <221> NAME/KEY: MOD\_RES

52 <222> LOCATION: (1)..(1)

53 <223> OTHER INFORMATION: 1,2-C6H4(CO)2-histidine

56 <220> FEATURE:

57 <221> NAME/KEY: MOD\_RES

58 <222> LOCATION: (3)..(3)

59 <223> OTHER INFORMATION: homophenylalanine

62 <400> SEQUENCE: 2

64 Xaa Gly Xaa Tyr Leu

65 1 5

67 <210> SEQ ID NO: 3

68 <211> LENGTH: 5

69 <212> TYPE: PRT

*per 1.823 of Sequence Rules, valid response is Artificial Sequence*  
*give source of genetic material - see item 12 on Error Summary sheet*

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:26

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

70 <213> ORGANISM: Artificial  
72 <220> FEATURE:  
73 <223> OTHER INFORMATION: no comment  
75 <220> FEATURE:  
76 <221> NAME/KEY: MOD\_RES  
77 <222> LOCATION: (1)..(1)  
78 <223> OTHER INFORMATION: acetyl-proline  
81 <400> SEQUENCE: 3  
OK 83 Xaa Leu Gly Leu Leu  
84 1 5  
86 <210> SEQ ID NO: 4  
87 <211> LENGTH: 5  
88 <212> TYPE: PRT  
89 <213> ORGANISM: Artificial  
91 <220> FEATURE:  
92 <223> OTHER INFORMATION: no comment  
94 <220> FEATURE:  
95 <221> NAME/KEY: MOD\_RES  
96 <222> LOCATION: (1)..(1)  
97 <223> OTHER INFORMATION: acetyl-proline  
100 <400> SEQUENCE: 4  
OK 102 Xaa Leu Gly Leu Leu  
103 1 5  
105 <210> SEQ ID NO: 5  
106 <211> LENGTH: 5  
107 <212> TYPE: PRT  
108 <213> ORGANISM: Artificial  
110 <220> FEATURE:  
111 <223> OTHER INFORMATION: no comment  
113 <220> FEATURE:  
114 <221> NAME/KEY: MOD\_RES  
115 <222> LOCATION: (2)..(2)  
116 <223> OTHER INFORMATION: beta alanine  
119 <220> FEATURE:  
120 <221> NAME/KEY: MOD\_RES  
121 <222> LOCATION: (1)..(1)  
122 <223> OTHER INFORMATION: acetyl-proline  
125 <400> SEQUENCE: 5  
OK 127 Xaa Xaa Gly Leu Leu  
128 1 5  
130 <210> SEQ ID NO: 6  
131 <211> LENGTH: 5  
132 <212> TYPE: PRT  
133 <213> ORGANISM: Artificial  
135 <220> FEATURE:  
136 <223> OTHER INFORMATION: no comment  
138 <220> FEATURE:  
139 <221> NAME/KEY: MOD\_RES  
140 <222> LOCATION: (2)..(2)

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:26

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

141 <223> OTHER INFORMATION: 4-aminobutyric acid

144 <220> FEATURE:

145 <221> NAME/KEY: MOD\_RES

146 <222> LOCATION: (1)..(1)

147 <223> OTHER INFORMATION: acetyl-proline

150 <400> SEQUENCE: 6

152 Xaa Xaa Gly Leu Leu

153 1 5

155 <210> SEQ ID NO: 7

156 <211> LENGTH: 5

157 <212> TYPE: PRT

158 <213> ORGANISM: Artificial

160 <220> FEATURE:

161 <223> OTHER INFORMATION: no comment

163 <220> FEATURE:

164 <221> NAME/KEY: MOD\_RES

165 <222> LOCATION: (2)..(2)

166 <223> OTHER INFORMATION: cyclohexylalanine

169 <220> FEATURE:

170 <221> NAME/KEY: MOD\_RES

171 <222> LOCATION: (1)..(1)

172 <223> OTHER INFORMATION: acetyl-proline

175 <400> SEQUENCE: 7

177 Xaa Xaa Gly Leu Leu

178 1 5

180 <210> SEQ ID NO: 8

181 <211> LENGTH: 5

182 <212> TYPE: PRT

183 <213> ORGANISM: Artificial

185 <220> FEATURE:

186 <223> OTHER INFORMATION: no comment

188 <400> SEQUENCE: 8

190 Pro Leu Gly Leu Leu

191 1 5

193 <210> SEQ ID NO: 9

194 <211> LENGTH: 5

195 <212> TYPE: PRT

196 <213> ORGANISM: Artificial

198 <220> FEATURE:

199 <223> OTHER INFORMATION: no comment

201 <220> FEATURE:

202 <221> NAME/KEY: MOD\_RES

203 <222> LOCATION: (1)..(1)

204 <223> OTHER INFORMATION: MeOCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>(=O)-proline

207 <400> SEQUENCE: 9

209 Xaa Leu Gly Leu Leu

210 1 5

212 <210> SEQ ID NO: 10

213 <211> LENGTH: 5

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:26

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

214 <212> TYPE: PRT  
215 <213> ORGANISM: Artificial  
217 <220> FEATURE:  
218 <223> OTHER INFORMATION: no comment  
220 <220> FEATURE:  
221 <221> NAME/KEY: MOD\_RES  
222 <222> LOCATION: (1)..(1)  
223 <223> OTHER INFORMATION: MeOCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>C(=O)-proline  
226 <400> SEQUENCE: 10  
OK 228 Xaa Leu Gly Leu Leu  
229 1 5  
231 <210> SEQ ID NO: 11  
232 <211> LENGTH: 5  
233 <212> TYPE: PRT  
234 <213> ORGANISM: Artificial  
236 <220> FEATURE:  
237 <223> OTHER INFORMATION: no comment  
239 <220> FEATURE:  
240 <221> NAME/KEY: MOD\_RES  
241 <222> LOCATION: (1)..(1)  
242 <223> OTHER INFORMATION: H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>C(=O)-proline  
245 <400> SEQUENCE: 11  
OK 247 Xaa Leu Gly Leu Leu  
248 1 5  
250 <210> SEQ ID NO: 12  
251 <211> LENGTH: 5  
252 <212> TYPE: PRT  
253 <213> ORGANISM: Artificial  
255 <220> FEATURE:  
256 <223> OTHER INFORMATION: no comment  
258 <220> FEATURE:  
259 <221> NAME/KEY: MOD\_RES  
260 <222> LOCATION: (1)..(1)  
261 <223> OTHER INFORMATION: AcHNCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>C(=O)-proline  
264 <400> SEQUENCE: 12  
OK 266 Xaa Leu Gly Leu Leu  
267 1 5  
269 <210> SEQ ID NO: 13  
270 <211> LENGTH: 5  
271 <212> TYPE: PRT  
272 <213> ORGANISM: Artificial  
274 <220> FEATURE:  
275 <223> OTHER INFORMATION: no comment  
277 <220> FEATURE:  
278 <221> NAME/KEY: MOD\_RES  
279 <222> LOCATION: (1)..(1)  
280 <223> OTHER INFORMATION: AcN(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NCH<sub>2</sub>C(=O)-proline  
283 <400> SEQUENCE: 13  
OK 285 Xaa Leu Gly Leu Leu

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:26

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

286 1 5  
288 <210> SEQ ID NO: 14  
289 <211> LENGTH: 4  
290 <212> TYPE: PRT  
291 <213> ORGANISM: Artificial  
293 <220> FEATURE:  
294 <223> OTHER INFORMATION: no comment  
296 <220> FEATURE:  
297 <221> NAME/KEY: MOD\_RES  
298 <222> LOCATION: (4)..(4)  
299 <223> OTHER INFORMATION: O-benzyl-serine  
302 <400> SEQUENCE: 14  
OK 304 Pro Leu Gly Xaa  
305 1  
307 <210> SEQ ID NO: 15  
308 <211> LENGTH: 4  
309 <212> TYPE: PRT  
310 <213> ORGANISM: Artificial  
312 <220> FEATURE:  
313 <223> OTHER INFORMATION: no comment  
315 <220> FEATURE:  
316 <221> NAME/KEY: MOD\_RES  
317 <222> LOCATION: (1)..(1)  
318 <223> OTHER INFORMATION: acetyl-proline  
321 <400> SEQUENCE: 15  
OK 323 Xaa Leu Gly Leu  
324 1  
326 <210> SEQ ID NO: 16  
327 <211> LENGTH: 5  
328 <212> TYPE: PRT  
329 <213> ORGANISM: Artificial  
331 <220> FEATURE:  
332 <223> OTHER INFORMATION: no comment  
334 <220> FEATURE:  
335 <221> NAME/KEY: MOD\_RES  
336 <222> LOCATION: (1)..(1)  
337 <223> OTHER INFORMATION: acetyl-glycine  
340 <400> SEQUENCE: 16  
OK 342 Xaa Pro Leu Gly Leu  
343 1 5  
345 <210> SEQ ID NO: 17  
346 <211> LENGTH: 6  
347 <212> TYPE: PRT  
348 <213> ORGANISM: Artificial  
350 <220> FEATURE:  
351 <223> OTHER INFORMATION: no comment  
353 <220> FEATURE:  
354 <221> NAME/KEY: MOD\_RES  
355 <222> LOCATION: (1)..(1)

Please correct these errors  
in subsequent sequences  
too.

**Please Note:**

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the  
Sequence Listing to ensure that a corresponding explanation is presented in the <220> to

VERIFICATION SUMMARY  
PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001  
TIME: 15:15:27

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03302001\I808832.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No  
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:39 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:102 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:127 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:152 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:177 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:209 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10  
L:247 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:266 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12  
L:285 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13  
L:304 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14  
L:323 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15  
L:342 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16  
L:373 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17  
L:398 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18  
L:429 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19  
L:460 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20  
L:491 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21  
L:516 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22  
L:541 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23  
L:566 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24  
L:591 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25  
L:616 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26  
L:641 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27  
L:666 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28  
L:691 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29  
L:710 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30  
L:729 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31  
L:748 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32  
L:773 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33  
L:804 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34  
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35  
L:842 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36  
L:861 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37  
L:886 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38  
L:905 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39  
L:924 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40  
L:943 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41  
L:962 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:42  
L:981 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:43  
L:1000 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44  
L:1019 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45  
L:1038 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46  
L:1057 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/808,832

DATE: 03/30/2001

TIME: 15:15:27

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03302001\I808832.raw

∴1076 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48  
∴1095 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49  
∴1114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50  
∴1133 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51